Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neuprex rBPI-21 bactericidal and endotoxin neutralizing agent: Began a Phase II trial in 72 patients in the Netherlands, with the primary endpoint of reducing c

XOMA Corp. (XOMA), Berkeley, Calif.
Product: Neuprex rBPI-21

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE